Halide (chloride, bromide) PEG
Reactive Intermediates, Synthesis
Article Body
Polyethylene glycol (PEG) is a versatile polymer that has found widespread applications in various fields, particularly in pharmaceuticals. Due to its excellent solubility, biocompatibility, and low toxicity, PEG has been approved by the FDA for use in injectable formulations and other pharmaceutical products. It can be tailored into a variety of forms and functions based on its molecular weight and structure, making it a critical component in drug formulation and delivery. This article explores the diverse applications of PEG in the pharmaceutical industry, including its use as a solvent, excipient, plasticizer, pore-forming agent, drug carrier, modifier, and penetration enhancer.
Polyethylene glycol is a versatile polymer composed of repeating units of ethylene oxide. It is widely recognized for its unique properties, including water solubility, biocompatibility, and low toxicity. These characteristics make PEG an essential material in various industries, particularly in pharmaceuticals, cosmetics, and biotechnology. PEG can exist in different physical forms: liquid, semi-solid, or solid, depending on its molecular weight, which typically ranges from 200 to 40,000 g/mol.
Fig. 1. Polyethylene glycol structure.
In the pharmaceutical field, PEG serves multiple roles, such as a solvent, stabilizer, and excipient. It is used in drug formulations to enhance solubility and bioavailability, and it can act as a carrier for active pharmaceutical ingredients (APIs). Additionally, PEG is employed in the process known as PEGylation, where it is conjugated to drugs or therapeutic proteins to improve their stability, prolong circulation time, and reduce immunogenicity. Beyond pharmaceuticals, PEG is used in cosmetics as a moisturizer and emulsifier, and in biotechnology for cell culture and protein purification. Its chemical versatility, non-toxicity, and ease of modification make PEG a fundamental component in many commercial and industrial applications.
| Cat. No. | Product Name | Category | Price |
|---|---|---|---|
| BPG-1626 | Polyethylene Glycol 200 | PEG Raw Materials | Inquiry |
| BPG-1627 | Polyethylene Glycol 400 | PEG Raw Materials | Inquiry |
| BPG-1628 | Polyethylene Glycol 600 | PEG Raw Materials | Inquiry |
| BPG-1629 | Polyethylene Glycol 800 | PEG Raw Materials | Inquiry |
| BPG-1630 | Polyethylene Glycol 1000 | PEG Raw Materials | Inquiry |
| BPG-1631 | Polyethylene Glycol 1500 | PEG Raw Materials | Inquiry |
| BPG-1632 | Polyethylene Glycol 2000 | PEG Raw Materials | Inquiry |
| BPG-1633 | Polyethylene Glycol 4000 | PEG Raw Materials | Inquiry |
| BPG-1634 | Polyethylene Glycol 6000 | PEG Raw Materials | Inquiry |
| BPG-1635 | Polyethylene Glycol 8000 | PEG Raw Materials | Inquiry |
| BPG-1636 | Polyethylene Glycol 10000 | PEG Raw Materials | Inquiry |
| BPG-1637 | Polyethylene Glycol 20000 | PEG Raw Materials | Inquiry |
Polyethylene glycol is classified based on its molecular weight, structure, and end-group functionality. This classification helps determine its suitability for various applications, from pharmaceuticals to industrial processes. The table below outlines the key classifications of PEG:
| Classification | Molecular Weight (g/mol) | Structure | Properties | Applications |
|---|---|---|---|---|
| Low Molecular Weight PEG | 200 - 600 | Linear | Liquid, high solubility, low viscosity | Solvents, drug solubilizers, injectable formulations, and eye drops. Suitable for enhancing solubility of hydrophobic drugs. |
| Medium Molecular Weight PEG | 1,000 - 6,000 | Linear | Semi-solid to waxy, moderate viscosity, water-soluble | Tablets, capsules, suppositories, ointments, and drug stabilizers. Used as a plasticizer, binder, or lubricant. |
| High Molecular Weight PEG | 8,000 - 35,000 | Linear | Solid, high melting point, low solubility | Controlled-release formulations, solid dispersions, excipients for sustained release of drugs, stabilizers, and binders in tablets. |
| PEG Derivatives | Varies | Branched or multi-arm | Enhanced functionality, customized reactivity | PEGylation for drug modification, bioconjugates, and drug delivery systems. Improves pharmacokinetics and reduces immunogenicity. |
| End-capped PEG | Varies | Linear with modified end-groups | Hydrophobic or hydrophilic end-groups, reactive functionalities | Surface modification, protein conjugation, and specialized drug delivery applications. Enhances material compatibility and therapeutic efficacy. |
| Crosslinked PEG | Varies | Networked hydrogel | Swellable, biodegradable, mechanical stability | Hydrogels for tissue engineering, wound dressings, and bioadhesives. Used in controlled drug delivery systems and regenerative medicine. |
PEG 200-600 water solutions at various concentrations serve as excellent solvents, capable of increasing the solubility of poorly soluble drugs and stabilizing drugs that are unstable in water, thus making them suitable for use as solvents in injectable preparations.
PEG 400 can be used as a solvent to formulate indomethacin eye drops, with PEG 400-based formulations showing better performance than those with Span 80. Additionally, PEG can act as a thickening agent in eye drops, increasing viscosity, prolonging the retention time of the drug in the eye, enhancing therapeutic efficacy, and reducing irritation.
Polyethylene glycol can form cosolvents with water in liquid excipients, enhancing the solubility of poorly soluble drugs.
PEG 4000 and PEG 6000 are commonly used as water-soluble binders and lubricants in tablet formulations. Granules produced using PEG as a binder have good formability, and the tablets remain non-hardening, suitable for granulation of both water-soluble and insoluble materials.
For example, adding polyethylene glycol to liquid protein drug formulations can modify the protein properties, increasing stability. High concentrations of PEG are often used as cryoprotectants and precipitating/crystallizing agents for proteins, interacting with the hydrophobic chains of proteins. Studies show that PEGs of different molecular weights have varying effects; for instance, 0.5% or 2% PEG 300 can inhibit the aggregation of recombinant human keratinocyte growth factor, while PEG 200, 400, 600, and 1000 can stabilize BSA and lysozyme.
Plasticizers are additives that increase the flexibility of materials. The choice of plasticizer greatly affects the drug release rate and properties of the coating. Polyethylene glycol is a commonly used plasticizer. Porogens, also known as release rate modifiers, are often water-soluble substances such as PEG, PVP, sucrose, and salts. For example, polyethylene glycol rapidly dissolves in water, forming diffusion channels for drug release, transforming the initial membrane into a porous one, enhancing membrane permeability, and improving drug release rate. Thus, PEG can be used as a porogen in membrane-controlled release formulations.
A suitable mixture of PEGs (such as equal parts of PEG 300 and PEG 500) provides a certain paste-like consistency with good water solubility and drug compatibility, making it an excellent water-soluble base material for ointments. Its advantages include non-irritation to the skin, stability without degradation, and no interference with sweating when applied to the skin. Since PEG is non-electrolytic, its pH can be adjusted to meet any required value for human use. Additionally, PEG can be used as a base material for suppositories. Due to its crystalline nature and water solubility, PEG is commonly used as a carrier for poorly soluble drugs, and suppositories formulated with PEG bases are less irritating than those using traditional fat bases.
PEG, with its good water solubility and ability to dissolve in various organic solvents, can disperse certain drugs at the molecular level, preventing drug aggregation. In solid dispersion materials, PEG acts as a water-soluble carrier material, increasing drug dissolution rates. PEG can also serve as a carrier material in sustained-release solid dispersions; for example, in the melting method, the drug is dissolved in molten PEG, filled into hard capsules, solidified at room temperature, and released slowly according to a dissolution mechanism. Different PEG contents can form various types of solid dispersions.
Research on polymer micelles mainly involves homopolymer and copolymer micelles. PEG can constitute the hydrophilic segment of amphiphilic block copolymers, forming various diblock or triblock copolymers with hydrophobic materials. These copolymers expand the range of drug carriers. For instance, copolymerization of PCL and PEG increases the hydrophilicity of PCL particles, forming amphiphilic copolymers that improve the micelle formation properties of polymers. Amphiphilic copolymers loaded with drugs form nanomicelles, where hydrophobic segments enhance the loading capacity for oil-soluble drugs like paclitaxel, while hydrophilic segments increase the water solubility of the drugs.
As a modification material, polyethylene glycol can modify drugs to alter their properties or modify drug carriers to improve their performance. PEG modifications can improve drug properties as follows: (1) increase stability and reduce enzymatic degradation; (2) improve pharmacokinetic properties, such as extending plasma half-life, reducing peak plasma concentration, and decreasing blood concentration fluctuations; (3) reduce immunogenicity and antigenicity; (4) reduce toxicity and enhance in vivo activity; (5) improve in vivo distribution and enhance targeting; (6) reduce dosing frequency and increase patient compliance.
Polyethylene glycol can chemically modify proteins through covalent bonding. PEGylation of proteins changes their biochemical characteristics, including size, hydrophobicity, and charge, thereby increasing protein solubility and stability. Additionally, PEGylation reduces protein immunogenicity and enhances drug efficacy and safety. PEG can be conjugated to amino, thiol, or carboxyl groups on proteins.
Preparation and in vitro drug release studies of PEG-modified polyamide-amine (PAMAM)-methotrexate (MTX) molecular complexes involve connecting functionalized PEG to PAMAM surface amino groups via amide bonds. The hemolytic toxicity of PEGylated PAMAM is investigated, and PAMAM-PEG/MTX complexes are prepared to determine their maximum complexation and study their in vitro drug release behavior in different buffer solutions and plasma under various storage conditions. Compared to PAMAM, PEGylated PAMAM shows significantly reduced hemolytic toxicity and has a certain sustained-release effect, making it a promising new drug delivery carrier material.
In addition to modifying proteins and carriers, polyethylene glycol is increasingly used to modify small-molecule drugs. For instance, PEG can modify small-molecule drugs using thionyl chloride as a coupling agent. After chlorocarbonylation, the drug is linked to PEG via degradable ester bonds. This method improves the yield of the target modification and enhances the water solubility of PEG-modified nicotinic acid.
Penetration enhancers are substances that can improve or accelerate the penetration of drugs through the skin. Ideal penetration enhancers should be non-damaging and non-irritating to the skin, pharmacologically inactive, non-allergenic, stable in physical and chemical properties, compatible with drugs and excipients, fast-acting, and long-lasting. Polyols, such as polyethylene glycol, isopropanol, and glycerol, are common penetration enhancers. The mechanism of action of polyols is to solvate proteins, occupy protein hydrogen-bond binding sites, reduce drug-tissue binding, and increase the distribution of other co-administered penetration enhancers in the stratum corneum.
Beyond its extensive use in pharmaceutics, polyethylene glycol plays a significant role in various biomedical fields:
** Recommended Products **
| Catalog | Name | CAS | Price |
|---|---|---|---|
| BPG-1695 | Fmoc-NH-PEG7-alcohol | 868594-44-9 | Inquiry |
| BPG-1973 | Azido-PEG5-azide | 356046-26-9 | Inquiry |
| BPG-2100 | Bromo-PEG5-bromide | 67705-77-5 | Inquiry |
| BPG-3582 | Mal-PEG7-Mal | 960257-46-9 | Inquiry |
| BPG-2266 | HO-PEG11-OH | 6809-70-7 | Inquiry |
| BPG-2295 | Biotin-PEG2-NH-Mal | 305372-39-8 | Inquiry |
| BPG-3568 | Bis-PEG3-NHS Ester | 1314378-16-9 | Inquiry |
| BPG-3557 | NHS-PEG4-azide | 944251-24-5 | Inquiry |
| BPG-3556 | Azido-PEG3-NHS ester | 1245718-89-1 | Inquiry |
| BPG-3555 | Azido-PEG2-NHS ester | 1312309-64-0 | Inquiry |
| BPG-3588 | Mal-PEG4-NHS | 1325208-25-0 | Inquiry |
| BPG-3587 | Mal-PEG2-NHS ester | 1433997-01-3 | Inquiry |
| BPG-2196 | Amino-PEG10-alcohol | 129449-09-8 | Inquiry |
| BPG-1767 | Azido-PEG3-amine | 134179-38-7 | Inquiry |
| BPG-1965 | HO-PEG7-OH | 5617-32-3 | Inquiry |
| BPG-1738 | Amino-PEG3-amine | 929-75-9 | Inquiry |
| BPG-0508 | m-PEG2-COOH | 149577-05-9 | Inquiry |
| BPG-0685 | Amino-PEG11-COOH | 1616426-12-0 | Inquiry |
| BPG-3491 | SPDP-PEG8-COOH | 1334177-96-6 | Inquiry |
| BPG-2262 | m-PEG10-COOH | 2409969-94-2 | Inquiry |
Planning to purchase or looking for custom solutions?
Get in touch with our experts today! We'll respond within 24 hours to discuss your project needs and provide a customized quote.
From custom PEG synthesis to PEGylation support, explore tailored services designed to meet the specific needs of your research.
Browse related content to gain a deeper understanding of PEG synthesis and manufacturing.

Halide (chloride, bromide) PEG
Reactive Intermediates, Synthesis

PEG Derivatives by Functional Groups
Bioconjugation, Custom Synthesis

Acrylate/Acrylamide/Methacrylate PEG
Hydrogels, Polymerization

Crosslinking, Surface Coating

Polymer Synthesis, Manufacturing

Lipid Delivery, Membrane Targeting

Nitrophenyl carbonate (NPC) PEG
Protein Modification, Coupling

Precise Conjugation, Uniformity

Disulfide Bonding, Conjugation

Click Chemistry, Conjugation
Online Inquiry